We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Boosts Product Portfolio With the Acquisition of Masimo
Read MoreHide Full Article
Key Takeaways
Danaher completed its $9.9B acquisition of Masimo, including assumed debt and acquired cash.
DHR gains sensor technologies, pulse oximetry and AI-enabled monitoring for diagnostics growth.
Masimo joins Danaher's Diagnostics segment; 2026 guidance update is planned after Q2 earnings.
Danaher Corporation (DHR - Free Report) has completed the acquisition of Masimo Corp. for $180 per share in cash. The transaction was valued at approximately $9.9 billion in total, including assumed debt and net of acquired cash.
Based in Irvine, CA, Masimo is engaged in developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. The company introduced Masimo SET Measure-through Motion and Low Perfusion pulse oximetry in 1995.
Acquisition Rationale of DHR
The latest buyout is in sync with Danaher’s policy of acquiring businesses to strengthen its business and expand market share. The integration of Masimo’s advanced sensor technologies, pulse oximetry solutions and AI-enabled patient-monitoring capabilities is expected to enhance the company’s diagnostics offerings. This acquisition will also enable DHR to provide more comprehensive solutions for acute-care settings, improving clinical decision-making and patient outcomes.
Masimo will operate as a standalone company within the Diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics.
Masimo Impact Limited in Q2
Danaher maintained its previously issued second-quarter and full-year 2026 guidance, excluding any contribution from Masimo. The company does not expect Masimo to have a material impact on its second-quarter 2026 results. However, DHR plans to update its full-year guidance when it reports second-quarter earnings to reflect the acquisition's expected contribution.
DHR’s Zacks Rank & Price Performance
Danaher is benefiting from strong demand in its bioprocessing business, fueled by rising demand for consumables from pharmaceutical customers. Strength in the filtration business, driven by increased demand for products in the microelectronic end market, also bodes well.
In the past month, this Zacks Rank #3 (Hold) company’s shares gained 8.9% compared with the industry’s 3.6% growth.
Image Source: Zacks Investment Research
However, the company is plagued by weakness in the Diagnostics segment. An increase in the cost of sales may affect the margin performance.
Stocks to Consider
Some better-ranked companies from the same space are discussed below:
ALHC delivered a trailing four-quarter average earnings surprise of 198.8%. In the past 30 days, the Zacks Consensus Estimate for Alignment Healthcare’s 2026 earnings has remained steady.
BrightSpring Health Services, Inc. (BTSG - Free Report) currently sports a Zacks Rank of 1. BTSG delivered a trailing four-quarter average earnings surprise of 14.6%.
In the past 30 days, the Zacks Consensus Estimate for BrightSpring’s 2026 earnings has remained steady.
CVS Health Corporation (CVS - Free Report) currently carries a Zacks Rank #2 (Buy). CVS delivered a trailing four-quarter average earnings surprise of 16.8%.
In the past 30 days, the Zacks Consensus Estimate for CVS Health’s 2026 earnings has increased 1.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Danaher Boosts Product Portfolio With the Acquisition of Masimo
Key Takeaways
Danaher Corporation (DHR - Free Report) has completed the acquisition of Masimo Corp. for $180 per share in cash. The transaction was valued at approximately $9.9 billion in total, including assumed debt and net of acquired cash.
Based in Irvine, CA, Masimo is engaged in developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. The company introduced Masimo SET Measure-through Motion and Low Perfusion pulse oximetry in 1995.
Acquisition Rationale of DHR
The latest buyout is in sync with Danaher’s policy of acquiring businesses to strengthen its business and expand market share. The integration of Masimo’s advanced sensor technologies, pulse oximetry solutions and AI-enabled patient-monitoring capabilities is expected to enhance the company’s diagnostics offerings. This acquisition will also enable DHR to provide more comprehensive solutions for acute-care settings, improving clinical decision-making and patient outcomes.
Masimo will operate as a standalone company within the Diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics.
Masimo Impact Limited in Q2
Danaher maintained its previously issued second-quarter and full-year 2026 guidance, excluding any contribution from Masimo. The company does not expect Masimo to have a material impact on its second-quarter 2026 results. However, DHR plans to update its full-year guidance when it reports second-quarter earnings to reflect the acquisition's expected contribution.
DHR’s Zacks Rank & Price Performance
Danaher is benefiting from strong demand in its bioprocessing business, fueled by rising demand for consumables from pharmaceutical customers. Strength in the filtration business, driven by increased demand for products in the microelectronic end market, also bodes well.
In the past month, this Zacks Rank #3 (Hold) company’s shares gained 8.9% compared with the industry’s 3.6% growth.
Image Source: Zacks Investment Research
However, the company is plagued by weakness in the Diagnostics segment. An increase in the cost of sales may affect the margin performance.
Stocks to Consider
Some better-ranked companies from the same space are discussed below:
Alignment Healthcare, Inc. (ALHC - Free Report) currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ALHC delivered a trailing four-quarter average earnings surprise of 198.8%. In the past 30 days, the Zacks Consensus Estimate for Alignment Healthcare’s 2026 earnings has remained steady.
BrightSpring Health Services, Inc. (BTSG - Free Report) currently sports a Zacks Rank of 1. BTSG delivered a trailing four-quarter average earnings surprise of 14.6%.
In the past 30 days, the Zacks Consensus Estimate for BrightSpring’s 2026 earnings has remained steady.
CVS Health Corporation (CVS - Free Report) currently carries a Zacks Rank #2 (Buy). CVS delivered a trailing four-quarter average earnings surprise of 16.8%.
In the past 30 days, the Zacks Consensus Estimate for CVS Health’s 2026 earnings has increased 1.1%.